On Wednesday, Shares of Nokia Corporation (ADR) (NYSE:NOK), gained 1.25% to $7.31.
A total of 275 899 571 new Nokia shares have been registered with the Trade Register. The shares were subscribed for by using the conversion right pertaining to Nokia’s EUR 750 million convertible bond. The conversion amount, EUR 659 400 000, is recorded into the fund for invested non-restricted equity, hence, the share capital of the company will not improvement.
The total number of Nokia shares after registration of the shares with the Trade Register is 3 954 650 462. Each share carries one vote.
The new shares will carry the shareholder rights under Finnish law as of the date of registration on November 11, 2015. The shares can commence trading in Nasdaq Helsinki together with other Nokia shares (NOKIA) as of November 11, 2015.
After registration the outstanding nominal value of the bonds, EUR 90 400 000, is convertible into maximum of 37 824 267 new Nokia shares. On October 8, 2015 Nokia sent a redemption notice to the holders of the convertible bond announcing that all the outstanding bonds will be redeemed and investors can convert bonds into Nokia shares until close of business in London on November 17, 2015. On November 26, 2015 all the outstanding bonds will be redeemed at their principal amount plus accrued but unpaid interest.
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally. The company operates through four segments: Mobile Broadband, Global Services, HERE, and Nokia Technologies.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD), declined -1.53% to $107.19, during its last trading session.
Gilead Sciences, declared that John F. Milligan, PhD, Gilead’s President and Chief Operating Officer, will take part in a fireside chat at the Credit Suisse 24th Annual Healthcare Conference in Scottsdale, Arizona on Tuesday, November 10at 10:30 a.m. Eastern Time.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Finally, Shares of 3D Systems Corporation (NYSE:DDD), ended its last trade with -6.12% loss, and closed at $9.05.
3D Systems, declared that it will be taking part in form next 2015, a new trade fair for moldmaking, product design and 3D printing that will be debuting this year in Frankfurt, Germany, November 17-20.
3DS will showcase the full power of its digital thread solutions for software and 3D printing, demonstrating the seamless design-to-manufacturing workflow it enables for professionals and businesses across industries. Among the products and capabilities on display will be the ProJet(R) 4500, ProJet 5500X and the CubePro desktop 3D printer. Visitors to the show will be able to witness firsthand the accuracy and detail of the Pro X(TM) 100 Direct Metal Printer as it creates highly complex metal parts live on the show floor.
3DS’ integrated solutions enhance, complement or replace traditional manufacturing methods through 3D scanning, design, production and inspection. These solutions lead to improved part performance and raised productivity within teams and organizations.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries.